Pleiotropic effects of statins

Indian Journal of Pharmacology

Volumn 37, Issue 2, 2005, Pages 77-85

  Tandon, V ^a   Bano, G ^a   Khajuria, V ^a   Parihar, A ^a   Gupta, S ^a  

^a GMC   (India)

Author keywords

Antioxidant; Antiplatelet activity; HMG CoA reductase inhibitors; Immunomodulation; Vascular disease

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; COLLAGEN; CYCLOOXYGENASE 2; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; MEVINOLIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BIOAVAILABILITY; CARDIOTOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM LESION; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOPOROSIS; OXIDATION; PLEIOTROPY; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STROKE; THYROID CARCINOMA; VITILIGO;

EID: 17444383423     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.15106     Document Type: Review

References (100)

1. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
2. Jones PH, Davidson MH, Stein EA, Bays HE, Mckenney JM, Miller E, et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR* Trail). Am J Cardiol 2003;92:152-60.
3. Shepherd J, Hunnighake DB, Barter P, Mckenney, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin and simvastatin for achieving lipid lowering goals. Am J Cardiol 2003;91 (Suppl):11-19.
4. Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: Association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin and simvastatin. Am J Cardiol 2003;91 (Suppl): 20-24.
5. Munford RS. Statins and the acute-phase response. N Engl J Med 2001;344:2016-18.
6. Blake GJ, Ridker PM. Are statins antiinflammatory? Curr Control Trials Cardiovasc Med 2000;1:161-5.
7. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methyl glutaryl co-enzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
8. Shishehbor MH, Brennam ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
9. Pliquett RU, Cornish KG, Peuler JD, Zucker IH. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003; 107:2493-8.
10. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6.
11. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-61.
12. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480-6.
13. Jones SP, Gibson MF, Rimmer III DM, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin a new HMG-CoA reductase inhibitor. JAm Coll Cardiol 2002;40:1172-8.
14. Xu Z, Zhao S, Zhou H, Ye H, Li J. Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin Chem 2004;50:750-3.
15. Efthimiodis AP, Psirropoulos D, Efthimidis T, Lefkos-N. Action of statins upon thrombogenesis, fibrinolysis and inflammation in coronary patients. Hippokratia 2002;6:186-92.
16. Tanaka K, Yasohara M, Suzumura K, Narita H, Suzuki T. Effects of fluvastatin and its major metabolities on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Jpn J Pharmacol 2001;86:289-96.
17. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immonomodulator. Nat Med 2000;6:1399-402.
18. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
19. Buffon A, Biasucci LM, Liuzzo G, D'Onofiro G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
20. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
21. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin M. Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease: FRISC study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139-47.
22. Chew DP, Bhatt DL, Robbins MA, Penn MS, Schneider JP, Lauer MS, et al. Incremental prognostic value of elevated baseline c-reactive protein among estabished markers of risk in percutaneous coronary intervention. Circulation 2001; 104: 992-7.
23. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
24. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
25. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atheroclerosis. Circulation 2001;103:1194-7.
26. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105:570-5.
27. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis and vascular remodeling. Circ Res 2001;89:1-2.
28. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102;1000-6.
29. Katritsis D, Korovesis S, Giazitzoglou E, Parissis J, Kalivas P, Webb-Peploe MM, et al. C-reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem 2001;47:882-6.
30. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
31. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA 2001;286:64-70.
32. Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, et al. Statin therapy, lipid levels. C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36:1774-80.
33. Serruys PW, De Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215-22.
34. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
35. th ed. New Delhi: Harcourt (India) Pvt. Ltd. 2003.
36. Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J Investig Med 2000;48:183-9.
37. Katoh M, Kurosawa Y, Tanaka K, Watanabe A, Doi H, Narita H. Fluvastatin inhibits O2-and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol 2001;281:655-60.
38. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-75.
39. Kreuzer J, Bader J, Jahn L, Hautmann M, Kubler W, Von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991;90:203-9.
40. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095-100.
41. Shiomi M, Ito T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999;126:961-8.
42. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrixproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
43. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103:993-9.
44. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry CJ, Shi L, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5.
45. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
46. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary endothelial cells. Life Sci 2000;67:863-76.
47. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
48. Palinski W: Immunomodulation: a new role for statins? Nat Med 2000;12:1311-2.
49. Cuthbert JA, Lipsky PE. Sterol metabolism and lymphocyte responsiveness: inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 1981;126:2093-9.
50. Cutts JL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme-A reductase by lovastatin. Int J Immunopharmacol 1989;11:863-9.
51. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydrox-3-methylglutary1 coenzyme-A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996;34:51-61.
52. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994;265:106-9.
53. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-4.
54. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human moncytes in vitro. Eur J Pharmacol 2000;410:83-92.
55. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-53.
56. Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction-clinical strategies for treating oxidant stress. Am Heart J 2003;146:218-26.
57. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methlglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;11:1712-9.
58. Wassmann S. Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-5.
59. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;47:1129-35.
60. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
61. Kureishi Y, Luo Z, Shiojima I, bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10. Erratum in: Nat Med 2001;7:129.
62. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, Trocha SD, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in Apo E deficient mice. Circulation 2001; 103: 2598-603.
63. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochem Biophys Acta 1993;1165:335-8.
64. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:122-8.
65. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
66. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome (1). N Engl J Med 1992;326: 242-50.
67. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-71.
68. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
69. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinase and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
70. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
71. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
72. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002;22:1452-8.
73. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J. Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103:926-33.
74. Bustos, C, Hernandez-Presa usa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32: 2057-64.
75. Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998;31: 773-8.
76. Rosenson RS. Non-lipid lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999;1:225-32.
77. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998;279:1643-50.
78. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000;87: 526-8.
79. Sander M, Hansen PG, Victor RG. Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995;26:691-5.
80. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin-II-induced renal injury independent of blood pressure and cholesterol-lowering effects. Kidney Int 2000;58:1420-30.
81. Hernandez-Perera O, Ferez-Sala D, Navarvo-Antolin J, Sanchez Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-9.
82. Glorisos N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.
83. Puddu P, Puddu GM, Muscari A. HMG-CoA reductase inhibitors: Is the endothelium the main target? Cardiology 2001;95:9-13.
84. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-73.
85. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002;51:334-42.
86. Puccetti L, Bruni F, Bova G, Cercignani M, Pompella G, Auteri A, et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. Int J Clin Lab Res 2000;30:147-56.
87. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000;67:427-31.
88. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
89. Austen B, Christodoulou G, Terry JE. Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging 2002;6:377-82
90. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003;88:3021-6.
91. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001;7:158-67.
92. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis 2001;22:1139-48.
93. Schlienger RG, Meier CR.HMG-CoA reductase inhibitors in osteoporosis: Do they reduce the risk of fracture? Drugs Aging 2003;20:321-36.
94. Lacroix AZ, Cauley JA, PettingerM,Hsia J, Bauer DC, McGowan J, et al. Statin use clinical fracture and bone density in postmenopausal women: Results from the women's health initiative observational study. Ann Intern Med 2003;139:97-104.
95. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003;17:905-7.
96. Liao JK. Statins and ischemic stroke. Atheroscler Suppl 2002;3:21-5.
97. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003;108:2113-20.
98. Noël M, Gagné C, Bergeron J, Jobin J, Poirier P. Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis 2004;3:7.
99. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-8.
100. McTaggart F, Buckett L, Davidson R, Holdgate G, Mc Cormick A, Schnech D, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28-32.